POINT IAS

‘FAITH’ Trials for COVID-19

Glenmark Pharmaceuticals has received approval from the Drugs Controller General of India (DCGI) to conduct phase 3 clinical trials for the efficacy of a combination of the antiviral drugs Favipiravir and Umifenovir as a potential treatment strategy for Covid-19. The new combination clinical trial will be called FAITH – (FA vipiravir plus Um I fenovir (efficacy and safety) Trial in Indian Hospital setting .

Categories: POINT IAS

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s